

Department of Neurology  
**Grand Rounds**

## “Parkinson’s Disease and Alpha-Synuclein: From Gene to Patient”

### Lorraine V. Kalia, MD, PhD, FRCPC

Assistant Professor, Division of Neurology, University of Toronto  
Staff Neurologist, Movement Disorders Centre, Toronto Western Hospital,  
University Health Network Scientist, Krembil Research Institute & Tanz Centre for  
Research in Neurodegenerative Diseases

**Friday, October 12, 2018**

**8:00 a.m.—9:00 a.m.**

**LIVE**—Manchester Pavilion, Building 200  
200 S. Manchester Ave.,  
Executive Classroom 212 (2nd floor)  
Orange, CA 92868

**Telecast**—UC Irvine main campus, Irvine Hall Conference Room 207  
and CHOC Commerce Tower, 12th floor, Conference Room 1200

**Target Audience:** This activity is being planned for UC Irvine’s Neurosciences faculty, residents and community physicians.

**Statement of Purpose:** To keep neurologists and other healthcare professionals updated on the latest clinical information in neurology.

**Accreditation Statement:** The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Designation Statement:** The University of California, Irvine School of Medicine designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Neurology Grand Rounds Global Objectives:** At the conclusion of this activity, the participant should be able to: (1)Discuss current issues relevant to the practice of neurology.(2)Identify new treatment techniques relevant to neurology. (3)Discuss updated practice guidelines. (4)Enhance awareness of neurological disorders, diagnosis, and treatment.

**Faculty Disclosure:** Dr. Lorraine V. Kalia has disclosed that she doesn’t have any relevant financial relationships to disclose.

**Course Director/Planners:** Tahseen Mozaffar, MD, as activity director, has disclosed that he is board member for aTyr Pharma, Ultragenyx, Alexion (Myasthenia Gravis), Amicus (Pompe Disease) and Sarepta, which could be perceived as a potential conflict of interest. Dr. Mozaffar further discloses that based his the potential conflict of interest, he will submit the program's curriculum in advance for peer review, and will defer to Drs. Mapstone, Sy, Stern-Nezer and Sen-Gupta in the planning of any content related to his disclosure information. Mark Mapstone, PhD; Indranil Sen-Gupta, MD; Michael Sy, MD, PhD; Sara Rebecca Jessica Stern-Nezer, MD and Carolina Villegas have disclosed that, as activity co-directors and planner, that they have no affiliations, arrangements, financial agreements which would be perceived as a potential conflict of interest.

**ADA Statement:** In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request. For any special requests, please contact Carolina Villegas at 714-509-2342 or [cvilleg1@uci.edu](mailto:cvilleg1@uci.edu) before the meeting date.